Key insights
- Moderna director Noubar Afeyan sold $433,878 in stock after exercising options. While the sale is a small fraction of his holdings and follows a standard option exercise, it occurs when the stock is up significantly and flagged as overvalued by some analyses. This insider selling, even if routine, can be perceived negatively by the market, potentially creating a slight bearish signal for MRNA.
Noubar Afeyan, a director at Moderna, Inc. (NASDAQ:MRNA), sold shares of the company’s common stock totaling $433,878 on May 21, 2026, according to a recent SEC Form 4 filing. The transaction involved the disposition of 9,263 shares at a price of $46.84 per share. The sale comes as Moderna’s stock trades at $46.88, up 75% over the past year, though InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value.
The sale followed an exercise of options to acquire the same number of shares on the same date. Flagship Pioneering, LLC, exercised options to purchase 9,263 shares of Moderna’s common stock at $19.15 per share, amounting to a total acquisition value of $177,386. These options were set to expire on August 10, 2026, and were fully vested and exercisable. Despite profitability challenges, InvestingPro data shows Moderna holds more cash than debt on its balance sheet, maintaining financial flexibility.
The securities involved in both the option exercise and subsequent sale are held indirectly by Flagship Pioneering, LLC. Mr. Afeyan is identified as the ultimate control person of Flagship Pioneering, LLC, but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Following these transactions, Mr. Afeyan’s indirect holdings through Flagship Pioneering, LLC, decreased to 3,924 shares. Additionally, Mr. Afeyan has indirect holdings of 3,880,328 shares through Flagship Ventures Fund IV, L.P., and 747,897 shares through Flagship Ventures Fund IV-Rx, L.P., for which he also disclaims beneficial ownership except for his pecuniary interest. He also holds 2,224,015 shares directly.
In other recent news, Moderna has made significant announcements that have caught the attention of investors. The company reported that its board of directors approved an amendment to its bylaws, designating federal district courts as the exclusive forum for certain legal complaints. This change aligns with recent legal amendments in Delaware. Additionally, Moderna held its 2026 Annual Meeting of Stockholders, confirming that a quorum was present for voting on agenda items. In a separate development, Moderna revealed plans for early-stage research into an mRNA-based hantavirus vaccine. This research is part of a collaboration with Korea University and the U.S. Army Medical Research Institute of Infectious Diseases. The company confirmed its commitment to this research, which has been highlighted in reports by Bloomberg. These developments come amid ongoing discussions about the potential for more hantavirus cases, as noted by the World Health Organization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates MRNA alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if MRNA is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?